全文获取类型
收费全文 | 8224篇 |
免费 | 440篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 224篇 |
妇产科学 | 200篇 |
基础医学 | 1255篇 |
口腔科学 | 171篇 |
临床医学 | 841篇 |
内科学 | 1658篇 |
皮肤病学 | 91篇 |
神经病学 | 563篇 |
特种医学 | 899篇 |
外国民族医学 | 2篇 |
外科学 | 899篇 |
综合类 | 41篇 |
一般理论 | 1篇 |
预防医学 | 455篇 |
眼科学 | 82篇 |
药学 | 540篇 |
中国医学 | 8篇 |
肿瘤学 | 691篇 |
出版年
2022年 | 52篇 |
2021年 | 131篇 |
2020年 | 64篇 |
2019年 | 102篇 |
2018年 | 125篇 |
2017年 | 93篇 |
2016年 | 116篇 |
2015年 | 134篇 |
2014年 | 200篇 |
2013年 | 242篇 |
2012年 | 387篇 |
2011年 | 328篇 |
2010年 | 209篇 |
2009年 | 214篇 |
2008年 | 327篇 |
2007年 | 356篇 |
2006年 | 370篇 |
2005年 | 353篇 |
2004年 | 336篇 |
2003年 | 322篇 |
2002年 | 325篇 |
2001年 | 360篇 |
2000年 | 345篇 |
1999年 | 253篇 |
1998年 | 128篇 |
1997年 | 123篇 |
1996年 | 87篇 |
1995年 | 79篇 |
1994年 | 63篇 |
1993年 | 65篇 |
1992年 | 137篇 |
1991年 | 156篇 |
1990年 | 139篇 |
1989年 | 168篇 |
1988年 | 139篇 |
1987年 | 131篇 |
1986年 | 107篇 |
1985年 | 123篇 |
1984年 | 83篇 |
1983年 | 72篇 |
1982年 | 65篇 |
1979年 | 92篇 |
1978年 | 54篇 |
1977年 | 54篇 |
1976年 | 64篇 |
1975年 | 54篇 |
1974年 | 67篇 |
1973年 | 63篇 |
1972年 | 56篇 |
1970年 | 54篇 |
排序方式: 共有8702条查询结果,搜索用时 15 毫秒
991.
Comparison of continuously acquired resting state and extracted analogues from active tasks 下载免费PDF全文
Sebastian Ganger Andreas Hahn Martin Küblböck Georg S. Kranz Marie Spies Thomas Vanicek René Seiger Ronald Sladky Christian Windischberger Siegfried Kasper Rupert Lanzenberger 《Human brain mapping》2015,36(10):4053-4063
Functional connectivity analysis of brain networks has become an important tool for investigation of human brain function. Although functional connectivity computations are usually based on resting‐state data, the application to task‐specific fMRI has received growing attention. Three major methods for extraction of resting‐state data from task‐related signal have been proposed (1) usage of unmanipulated task data for functional connectivity; (2) regression against task effects, subsequently using the residuals; and (3) concatenation of baseline blocks located in‐between task blocks. Despite widespread application in current research, consensus on which method best resembles resting‐state seems to be missing. We, therefore, evaluated these techniques in a sample of 26 healthy controls measured at 7 Tesla. In addition to continuous resting‐state, two different task paradigms were assessed (emotion discrimination and right finger‐tapping) and five well‐described networks were analyzed (default mode, thalamus, cuneus, sensorimotor, and auditory). Investigating the similarity to continuous resting‐state (Dice, Intraclass correlation coefficient (ICC), R2) showed that regression against task effects yields functional connectivity networks most alike to resting‐state. However, all methods exhibited significant differences when compared to continuous resting‐state and similarity metrics were lower than test‐retest of two resting‐state scans. Omitting global signal regression did not change these findings. Visually, the networks are highly similar, but through further investigation marked differences can be found. Therefore, our data does not support referring to resting‐state when extracting signals from task designs, although functional connectivity computed from task‐specific data may indeed yield interesting information. Hum Brain Mapp 36:4053–4063, 2015. © 2015 The Authors Human Brain Mapping Published by Wiley Periodicals, Inc. 相似文献
992.
Targeting ASCT2‐mediated glutamine uptake blocks prostate cancer growth and tumour development 下载免费PDF全文
Qian Wang Rae‐Anne Hardie Andrew J Hoy Michelle van Geldermalsen Dadi Gao Ladan Fazli Martin C Sadowski Seher Balaban Mark Schreuder Rajini Nagarajah Justin J‐L Wong Cynthia Metierre Natalia Pinello Nicholas J Otte Melanie L Lehman Martin Gleave Colleen C Nelson Charles G Bailey William Ritchie John EJ Rasko Jeff Holst 《The Journal of pathology》2015,236(3):278-289
993.
Ji-Young Hwang Boo-Kyung Han Eun Young Ko Jung Hee Shin Soo Yeon Hahn Mee Young Nam 《Yonsei medical journal》2015,56(5):1352-1358
Purpose
To show the results of an audit of screening breast ultrasound (US) in women with negative mammography in a single institution and to analyze US-detected cancers within a year and interval cancers.Materials and Methods
During the year of 2006, 1974 women with negative mammography were screened with US in our screening center, and 1727 among them had pathologic results or any follow up breast examinations more than a year. We analyzed the distribution of Breast Imaging Reporting and Data System (BI-RADS) category and the performance outcome through follow up.Results
Among 1727 women (age, 30-76 years, median 49.5 years), 1349 women (78.1%) showed dense breasts on mammography, 762 (44.1%) had previous breast US, and 25 women (1.4%) had a personal history of breast cancers. Test negatives were 94.2% (1.627/1727) [BI-RADS category 1 in 885 (51.2%), 2 in 742 (43.0%)]. The recall rate (=BI-RADS category 3, 4, 5) was 5.8%. Eight cancers were additionally detected with US (yield, 4.6 per 1000). The sensitivity, specificity, and positive predictive value (PPV1, PPV2) were 88.9%, 94.6%, 8.0%, and 28.0%, respectively. Eight of nine true positive cancers were stage I or in-situ cancers. One interval cancer was stage I cancer from BI-RADS category 2.Conclusion
Screening US detected 4.6 additional cancers among 1000. The recall rate was 5.8%, which is in lower bound of acceptable range of mammography (5-12%), according to American College of Radiology standard. 相似文献994.
Hahn A Ankermann T Claass A Mann M Lindemann H Neubauer BA 《Pediatric pulmonology》2008,43(10):973-981
The non-invasive tension-time index of the inspiratory muscles at rest (TTMUS) can be used for assessing respiratory muscle function in children with cystic fibrosis (CF). This study aimed to investigate how TTMUS becomes altered with increasing pulmonary impairment, and which factors determine TTMUS changes in CF. We assessed TTMUS in 47 patients with stable CF ranging in age from 9 to 26 years and in 47 controls of same age and gender. Pulmonary impairment was assessed by the pulmonary function score (PFS) according to Cropp (PFS 0-2 = no, 3-7 = mild, 8-12 = moderate, and 13-18 = severe dysfunction). Median TTMUS was significantly higher in the entire CF-group than in controls ((0.112 (0.079-0.174) vs. 0.07 (0.052-0.094), P < 0.001)). It was nearly identical in CF-patients without (0.079 (0.056-0.114)) and mild (0.080 (0.059-0.128)) pulmonary dysfunction. It was non-significantly higher in subjects with moderate (0.118 (0.103-0.173)) and grossly elevated in individuals with severe (0.232 (0.211-0.31), P < 0.001)) respiratory impairment when compared to the other PFS-groups. TTMUS was significantly related to percent predicted airway resistance (Raw%pred) (r = 0.60, P < 0.001), percent predicted Forced Expiratory Volume in 1 sec (r = -0.49, P < 0.001), percent predicted Vital Capacity (-0.57, P < 0.001), Functional Residual Capacity in percent Total Lung Capacity (r = 0.42, P = 0.003), and transcutaneous oxygen saturation (r = -0.49, P < 0.001). By contrast, Raw%pred was the only variable that had a significant effect on TTMUS (P = 0.01), when a multivariate logistic regression was applied, using the median of the entire CF-cohort to dichotomise TTMUS. These findings suggest that subjects with stable CF and severe pulmonary dysfunction are prone to respiratory muscle fatigue, and that airway obstruction is an important factor contributing to the increase of TTMUS in CF. Regular determination of TTMUS may be clinically useful during course of disease, and may aid the decision to institute therapies like respiratory muscle training or non-invasive intermittent ventilation. 相似文献
995.
Jonathan Richard Maxime Veillette Nathalie Brassard Shilpa S. Iyer Michel Roger Lo?c Martin Marzena Pazgier Arne Sch?n Ernesto Freire Jean-Pierre Routy Amos B. Smith III Jongwoo Park David M. Jones Joel R. Courter Bruno N. Melillo Daniel E. Kaufmann Beatrice H. Hahn Sallie R. Permar Barton F. Haynes Navid Madani Joseph G. Sodroski Andrés Finzi 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(20):E2687-E2694
HIV-1-infected cells presenting envelope glycoproteins (Env) in the CD4-bound conformation on their surface are preferentially targeted by antibody-dependent cell-mediated cytotoxicity (ADCC). HIV-1 has evolved a sophisticated mechanism to avoid exposure of ADCC-mediating Env epitopes by down-regulating CD4 and by limiting the overall amount of Env at the cell surface. Here we report that small-molecule CD4-mimetic compounds induce the CD4-bound conformation of Env, and thereby sensitize cells infected with primary HIV-1 isolates to ADCC mediated by antibodies present in sera, cervicovaginal lavages, and breast milk from HIV-1-infected individuals. Importantly, we identified one CD4 mimetic with the capacity to sensitize endogenously infected ex vivo-amplified primary CD4 T cells to ADCC killing mediated by autologous sera and effector cells. Thus, CD4 mimetics hold the promise of therapeutic utility in preventing and controlling HIV-1 infection.Worldwide, it is estimated that more than 35 million people are living with HIV. In 2013 alone, around 2.1 million people became newly infected with HIV, and 1.5 million people died from AIDS (1). Measures to prevent HIV-1 transmission are desperately needed. Prevention of HIV-1 transmission and progression likely requires approaches that can specifically target and eliminate HIV-1-infected cells. Interestingly, there is increasing evidence supporting a role of antibody (Ab)-dependent cell-mediated cytotoxicity (ADCC) in controlling HIV-1 transmission and disease progression (2–8). Analysis of the correlates of protection in the RV144 vaccine trial suggested that increased ADCC activity was linked with decreased HIV-1 acquisition (9), and Abs with potent ADCC activity were isolated from some RV144 vaccinees (10). Recent studies reported that the viral accessory proteins Nef and Vpu protect HIV-1-infected cells from anti-HIV-1 envelope (Env)-mediated ADCC responses (11–14). Importantly, we and others reported that Env in the CD4-bound conformation was preferentially targeted by ADCC-mediating Abs and sera from HIV-1-infected individuals (11, 12, 15, 16), which represent a significant proportion of anti-Env Abs elicited during natural HIV infection (11, 17). However, the vast majority of circulating HIV-1 strains worldwide express functional Nef and Vpu proteins, which limit the exposure of CD4-induced (CD4i) Env epitopes at the surface of infected cells, likely preventing ADCC responses.Theoretically, agents promoting the CD4-bound Env conformation should expose CD4i epitopes that are readily recognized by ADCC-mediating Abs and sera from infected individuals (11, 12, 15, 16, 18), resulting in the sensitization of HIV-1-infected cells to ADCC. Importantly, modulating Env conformation at the surface of HIV-1-infected cells has become feasible as a result of the availability of small CD4-mimetic compounds (CD4mc). The prototypes of such compounds, NBD-556 and NBD-557, were discovered in a screen for inhibitors of gp120-CD4 interaction (19). These small-molecule ∼337-Da compounds and recent derivatives (DMJ-I-228, JP-III-48) bind in the Phe-43 cavity (20–22), a highly conserved ∼150-Å3 pocket in the gp120 glycoprotein located at the interface of the inner domain, outer domain, bridging sheet, and CD4 receptor (23). CD4mc block gp120-CD4 interaction and induce thermodynamic changes in gp120 similar to those observed during CD4 or soluble CD4 (sCD4) binding (24). Accordingly, these small molecules, as well as sCD4, can promote the transition of Env to the CD4-bound conformation, thus sensitizing HIV-1 particles to neutralization by otherwise nonneutralizing CD4i Abs (17, 25). Additional strategies using scaffolded miniproteins targeting critical gp120 elements required for CD4 interaction allowed the identification of CD4 mimetics with nanomolar affinity for gp120 (26). One of these variants, M48U1, displayed remarkably potent neutralization of three HIV-1 isolates (27). Its crystal structure in complex with HIV-1 gp120 was recently solved, showing that M48U1 engages the Phe-43 cavity in a manner similar to that of CD4 (28); thus, M48U1 might induce gp120 to adopt the CD4-bound conformation and expose CD4i epitopes. Previous studies exploring the antiviral properties of CD4mc were performed on viral particles (17, 25, 27). However, whether these compounds are able to engage the large amounts of Env present at the surface of infected cells and modulate Env conformation in a way that allows exposure of ADCC-mediating epitopes is currently not known. In this study, we show that CD4mc strongly sensitize HIV-1-infected primary CD4 T cells to ADCC mediated by sera, cervicovaginal fluids, and breast milk from HIV-1-infected individuals, as well as help eliminate infected, ex vivo-expanded primary CD4 T cells from HIV-1-infected individuals. Therefore, CD4mc possess three valuable complementary antiviral properties: direct inactivation of viral particles, sensitization of viral particles to neutralization by otherwise nonneutralizing Abs, and sensitization of HIV-1-infected cells to ADCC-mediated killing. 相似文献
996.
With nearly 50 % of all colorectal cancers being diagnosed in patients at the age of 70 or above colorectal cancer is a disease of the elderly. In an adjuvant setting, fit elderly patients can receive the same benefit from cytotoxic therapy as younger patients with an only slightly increased toxicity. In a palliative setting, the treatment of elderly patients with respect to clinical endpoints such as response, time to progression or overall survival is as effective as in their younger counterparts. In clinical studies, older patients are generally underrepresented and among the elderly patients involved in clinical studies there is a bias towards particularly fit patients. Therefore it is not possible to extrapolate the results of many randomized trials to all elderly patients. A Comprehensive Geriatric Assessment (CGA) should be applied to detect the diversities in the geriatric population. Based on this assessment elderly patients classified as suitable for chemotherapy should be enrolled into clinical trials for colorectal cancer. 相似文献
997.
Steve Schulz Anett Stephan Simone Hahn Luisa Bortesi Franziska Jarczowski Ulrike Bettmann Anne-Katrin Paschke Daniel Tusé Chad H. Stahl Anatoli Giritch Yuri Gleba 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(40):E5454-E5460
Enterohemorrhagic Escherichia coli (EHEC) is one of the leading causes of bacterial enteric infections worldwide, causing ∼100,000 illnesses, 3,000 hospitalizations, and 90 deaths annually in the United States alone. These illnesses have been linked to consumption of contaminated animal products and vegetables. Currently, other than thermal inactivation, there are no effective methods to eliminate pathogenic bacteria in food. Colicins are nonantibiotic antimicrobial proteins, produced by E. coli strains that kill or inhibit the growth of other E. coli strains. Several colicins are highly effective against key EHEC strains. Here we demonstrate very high levels of colicin expression (up to 3 g/kg of fresh biomass) in tobacco and edible plants (spinach and leafy beets) at costs that will allow commercialization. Among the colicins examined, plant-expressed colicin M had the broadest antimicrobial activity against EHEC and complemented the potency of other colicins. A mixture of colicin M and colicin E7 showed very high activity against all major EHEC strains, as defined by the US Department of Agriculture/Food and Drug Administration. Treatments with low (less than 10 mg colicins per L) concentrations reduced the pathogenic bacterial load in broth culture by 2 to over 6 logs depending on the strain. In experiments using meats spiked with E. coli O157:H7, colicins efficiently reduced the population of the pathogen by at least 2 logs. Plant-produced colicins could be effectively used for the broad control of pathogenic E. coli in both plant- and animal-based food products and, in the United States, colicins could be approved using the generally recognized as safe (GRAS) regulatory approval pathway.Enterohemorrhagic Escherichia coli (EHEC), a subset of Shiga toxin-producing E. coli (STEC) strains, is a leading cause of bacterial enteric infections in the United States and worldwide. EHEC causes ∼100,000 illnesses, 3,000 hospitalizations, and 90 deaths annually in the United States alone (1). Most of these illnesses have been linked to consumption of foods derived from animal products and, recently, organically grown vegetables. Nearly a quarter of all documented cases of EHEC in the United States last year were associated with fruits and vegetables, especially organically grown produce (www.cdc.gov/foodsafety/pdfs/foodborne-disease-outbreaks-annual-report-2013-508c.pdf). Although O157:H7 is currently the predominant serotype and accounts for ∼75% of EHEC infections worldwide, several non-O157 EHEC serotypes are also emerging as serious concerns for foodborne illnesses. In the United States, a group often referred to as the “Big 6” (O111, O26, O121, O103, O145, and O45) accounts for the majority of the non-O157:H7 serotypes isolated from clinical infections and, therefore, is also a focus of concern (2). One of the most serious recent cases of E. coli contamination outside the United States occurred in Europe in 2011, when fenugreek seeds contaminated with O104:H4 E. coli in an organic sprouts farm afflicted nearly 4,000 people, ultimately causing 54 deaths (3).Currently, there are very few interventions targeted toward the inactivation of bacteria on food. Most of the available interventions involve heating or organic acids, which can adversely modify the taste and quality of the products. Currently approved bacteriophage mixtures enable narrow and specific control of O157:H7 but not of other pathogenic strains (4). Use of traditional antibiotics for the treatment of food is not appropriate and should be considered unacceptable, particularly due to the increase of antibiotic resistance seen among E. coli strains found in food (5). Among nonantibiotic antibacterials, several colicins have been shown to be highly effective against some EHEC strains, each individually reducing the bacterial load by up to 5 logs; some of them were found to be an effective treatment for reducing EHEC populations in both live animals and animal-derived products (6, 7).Colicins are a group of bacteriocin-class antimicrobial proteins produced by, and effective against, E. coli and very closely related bacteria. Research on colicins began with their initial discovery 90 y ago (8). Colicins are classified based on their mode of bactericidal activity (either enzymatic inhibition of DNA, RNA, or cell-wall synthesis or depolarization via a pore-forming effect), their membrane receptors, and the mechanism they use for translocation through the outer membrane and across the periplasmic space of gram-negative bacteria. There are limited data on the effects of colicins on major foodborne E. coli strains (e.g., 7, 9, 10). We demonstrate here that we were able to express most colicins in plants with very high yields (up to 30% of total soluble protein, or 3 g active protein per kg of fresh green biomass) and at manufacturing costs that would allow commercial adoption of the technology. Production host plants can include tobacco and edible species such as spinach and leafy beets. Among the different colicins evaluated, colicin M was found to possess the broadest antimicrobial activity against major pathogenic E. coli strains. Because of their different mechanisms of action, mixtures of colicins can be used to exert complementary (additive) control of pathogens. Mixtures of colicin M and other colicins, and of colicin M and colicin E7 in particular, show very high activity against all seven pathogenic serotypes defined by the United States Department of Agriculture (USDA)/Food and Drug Administration (FDA) as major foodborne pathogens. These mixtures were also effective in controlling the emerging pathogenic serotype O104:H4. Treatments with colicin mixtures at low levels (nanomolar concentrations, or less than 10 mg total colicins per kg of treated food product) reduce the bacterial load of different pathogenic strains by 2 to >6 logs.We propose using plant-produced colicins on food to enable broad control of pathogenic E. coli bacteria in animal- and plant-derived products. Because the compositions of plant-produced colicins are identical to those of native colicins produced by colicinogenic strains in many environments, including the gastrointestinal (GI) tract of humans and other animals, colicins are recognized as safe through an extensive history of human exposure, and therefore in the United States they can be approved using the GRAS (generally recognized as safe) regulatory approval pathway. 相似文献
998.
Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non–small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results 下载免费PDF全文
999.
We previously reported that aberrant HH pathway activation confers a poor prognosis in rhabdomyosarcoma (RMS). Searching for new treatment strategies we therefore targeted HH signaling. Here, we identify a novel synthetic lethality of concomitant inhibition of HH and PI3K/AKT/mTOR pathways in RMS by GLI1/2 inhibitor GANT61 and PI3K/mTOR inhibitor PI103. Synergistic drug interaction is confirmed by calculation of combination index (CI < 0.2). Similarly, genetic silencing of GLI1/2 significantly increases PI103-induced apoptosis. GANT61 and PI103 also synergize to induce apoptosis in cultured primary RMS cells emphasizing the clinical relevance of this combination. Importantly, GANT61/PI103 cotreatment suppresses clonogenic survival, three-dimensional sphere formation and tumor growth in an in vivo model of RMS. Mechanistic studies reveal that GANT61 and PI103 cooperate to trigger caspase-dependent apoptosis via the mitochondrial pathway, as demonstrated by several lines of evidence. First, GANT61/PI103 cotreatment increases mRNA and protein expression of NOXA and BMF, which is required for apoptosis, since knockdown of NOXA or BMF significantly reduces GANT61/PI103-induced apoptosis. Second, GANT61/PI103 cotreatment triggers BAK/BAX activation, which contributes to GANT61/PI103-mediated apoptosis, since knockdown of BAK provides protection. Third, ectopic expression of BCL-2 or non-degradable phospho-mutant MCL-1 significantly rescue GANT61/PI103-triggered apoptosis. Fourth, GANT61/PI103 cotreatment initiate activation of the caspase cascade via apoptosome-mediated cleavage of the initiator caspase-9, as indicated by changes in the cleavage pattern of caspases (e.g. accumulation of the caspase-9 p35 cleavage fragment) upon addition of the caspase inhibitor zVAD.fmk. Thus, combined GLI1/2 and PI3K/mTOR inhibition represents a promising novel approach for synergistic apoptosis induction and tumor growth reduction with implications for new treatment strategies in RMS. 相似文献